CTLA4 and hepatocellular carcinoma: The present study revealed a significant association between positive expression of CTLA-4 and PD-1 and higher IPS in the high-risk patient group, indicating that inhibiting the PD-1 and CTLA-4 can enhance the abundance of CD8T cells within the TME, thereby further augmenting the efficacy of immunotherapy in HCC patients.